PET imaging agent for prostate cancer
Fully diluted ownership
Value of Syncona holding
£115.5m (as at 31 August 2017)
Blue Earth Diagnostics Ltd. (“BED”) was founded in March 2014 to develop and commercialise molecular imaging agents addressing areas of high un-met medical need.
Axumin has been developed and proven clinically to target and image prostate cancer cells. Axumin was reviewed by the US Food and Drug Administration (FDA) and was granted US regulatory approval in Q2 2016.
Prostate cancer is a leading cause of cancer death in men, second only to lung cancer, and a growing cost burden to healthcare systems worldwide. There were around 180,000 new cases and 26,000 deaths in the US in 2016.
- Martin Murphy
- Iraj Ali
- Elisa Petris
President, BED Inc.
- Mike Heslop